BBA
MNTA

Baker Bros. Advisors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Baker Bros. Advisors’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-308,500
Closed -$8.11M – 98
2018
Q3 		$8.11M Hold
308,500
– – 0.05% 58
2018
Q2 		$6.31M Hold
308,500
– – 0.05% 64
2018
Q1 		$5.6M Buy
+308,500
New +$5.14M 0.05% 75

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Baker Bros. Advisors's MNTA Position: Q4 2018 in Review

Baker Bros. Advisors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2018, closing a stake of 308,500 shares — an estimated $8.11M sold.

Baker Bros. Advisors first reported a position in MNTA in Q1 2018 and held it in 3 quarters. The position peaked at $8.11M in Q3 2018. 158 funds tracked by Wall St. Rank hold MNTA as of Q4 2018.

  • Baker Bros. Advisors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Baker Bros. Advisors sold 308,500 Momenta Pharmaceuticals, Inc. shares in Q4 2018, an estimated $8.11M.
  • Baker Bros. Advisors first reported a position in Momenta Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
  • Baker Bros. Advisors's Momenta Pharmaceuticals, Inc. position peaked at $8.11M in Q3 2018.
  • 158 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2018.

Based on Baker Bros. Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.